Date:_ 12/27/2022
Your Name: Karina Pogosian
<b>Manuscript Title:</b> _11C-methionine PET/CT and conventional imaging techniques in the diagnosis of primary
hyperparathyroidism
Manuscript number (if known): QIMS-22-584

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	This work was financially supported by the Ministry of Science and Higher Education of the Russian Federation [Agreement No. 075- 15-2022-301]			
	Time frame: past 36 months				

2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	X None	
5	Payment or honoraria for	Y Nere	
5		<b>X</b> None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6		M. Nama	
0	Payment for expert	<b>X</b> None	
	testimony		
	-		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
Ŭ	pending		
	P 0.10118		
9	Participation on a Data	Y Nore	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
	-		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
1	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<b>X</b> None	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

Date:_ 12/27/2022
Your Name: Tatiana Karonova
Manuscript Title:_11C-methionine PET/CT and conventional imaging techniques in the diagnosis of primary
hyperparathyroidism
Manuscript number (if known): QIMS-22-584

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	This work was financially supported by the Ministry of Science and Higher Education of the Russian Federation [Agreement No. 075- 15-2022-301]			
	Time frame: past 36 months				

2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	X None	
5	Payment or honoraria for	Y Nere	
5		<b>X</b> None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6		M. Nama	
0	Payment for expert	<b>X</b> None	
	testimony		
	-		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
Ŭ	pending		
	P 0.10118		
9	Participation on a Data	Y Nore	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
	-		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
1	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<b>X</b> None	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

Date:_ 12/27/2022
Your Name: Daria Ryzhkova
Manuscript Title:_11C-methionine PET/CT and conventional imaging techniques in the diagnosis of primary
hyperparathyroidism
Manuscript number (if known): QIMS-22-584

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	This work was financially supported by the Ministry of Science and Higher Education of the Russian Federation [Agreement No. 075- 15-2022-301]			
	Time frame: past 36 months				

2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	X None	
5	Payment or honoraria for	Y Nere	
5		<b>X</b> None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6		M. Nama	
0	Payment for expert	<b>X</b> None	
	testimony		
	-		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
Ŭ	pending		
	P 0.10118		
9	Participation on a Data	Y Nore	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
	-		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
1	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<b>X</b> None	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

Date:_ 12/27/2022
Your Name: Liubov Yanevskaya
Manuscript Title:_11C-methionine PET/CT and conventional imaging techniques in the diagnosis of primary
hyperparathyroidism
Manuscript number (if known):QIMS-22-584
· · · · · · · · · · · · · · · · · · ·

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	This work was financially supported by the Ministry of Science and Higher Education of the Russian Federation [Agreement No. 075- 15-2022-301]			
	Time frame: past 36 months				

2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	X None	
5	Payment or honoraria for	Y Nere	
5		<b>X</b> None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6		M. Nama	
0	Payment for expert	<b>X</b> None	
	testimony		
	-		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
Ŭ	pending		
	P 0.10118		
9	Participation on a Data	Y Nore	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
	-		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
1	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<b>X</b> None	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

Date:_ 12/27/2022
Your Name: Uliana Tsoy
Manuscript Title:_11C-methionine PET/CT and conventional imaging techniques in the diagnosis of primary
hyperparathyroidism
Manuscript number (if known): QIMS-22-584

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	This work was financially supported by the Ministry of Science and Higher Education of the Russian Federation [Agreement No. 075- 15-2022-301]			
	Time frame: past 36 months				

2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	X None	
5	Payment or honoraria for	Y Nere	
5		<b>X</b> None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6		M. Nama	
0	Payment for expert	<b>X</b> None	
	testimony		
	-		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
Ŭ	pending		
	P 0.10118		
9	Participation on a Data	Y Nore	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
	-		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
1	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<b>X</b> None	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

Date:_ 12/27/2022
Your Name: Olga Yudina
Manuscript Title:_11C-methionine PET/CT and conventional imaging techniques in the diagnosis of primary
hyperparathyroidism
Manuscript number (if known): QIMS-22-584

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	This work was financially supported by the Ministry of Science and Higher Education of the Russian Federation [Agreement No. 075- 15-2022-301]			
	Time frame: past 36 months				

2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	X None	
5	Payment or honoraria for	Y Nere	
5		<b>X</b> None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6		M. Nama	
0	Payment for expert	<b>X</b> None	
	testimony		
	-		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
Ŭ	pending		
	P 0.10118		
9	Participation on a Data	Y Nore	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
	-		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
1	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<b>X</b> None	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

Date:_ 12/27/2022
Your Name: Gleb Berkovich
Manuscript Title:_11C-methionine PET/CT and conventional imaging techniques in the diagnosis of primary
hyperparathyroidism
Manuscript number (if known): QIMS-22-584

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	This work was financially supported by the Ministry of Science and Higher Education of the Russian Federation [Agreement No. 075- 15-2022-301]			
	Time frame: past 36 months				

2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	X None	
5	Payment or honoraria for	Y Nere	
5		<b>X</b> None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6		M. Nama	
0	Payment for expert	<b>X</b> None	
	testimony		
	-		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
Ŭ	pending		
	P 0.10118		
9	Participation on a Data	Y Nore	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
	-		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
1	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<b>X</b> None	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

Date:_ 12/27/2022
Your Name: Anna Dalmatova
Manuscript Title:_11C-methionine PET/CT and conventional imaging techniques in the diagnosis of prima
hyperparathyroidism
Manuscript number (if known): QIMS-22-584

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	This work was financially supported by the Ministry of Science and Higher Education of the Russian Federation [Agreement No. 075- 15-2022-301]			
	Time frame: past 36 months				

2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	X None	
5	Payment or honoraria for	Y Nere	
5		<b>X</b> None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6		M. Nama	
0	Payment for expert	<b>X</b> None	
	testimony		
	-		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
Ŭ	pending		
	P 0.10118		
9	Participation on a Data	Y Nore	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
	-		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
1	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<b>X</b> None	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

Date:_ 12/27/2022
Your Name: Elena Grineva
Manuscript Title:_11C-methionine PET/CT and conventional imaging techniques in the diagnosis of primary
hyperparathyroidism
Manuscript number (if known): QIMS-22-584

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	This work was financially supported by the Ministry of Science and Higher Education of the Russian Federation [Agreement No. 075- 15-2022-301]			
	Time frame: past 36 months				

	<u> </u>	
	Grants or contracts from	XNone
	any entity (if not indicated	
	in item #1 above).	
3	Royalties or licenses	XNone
4	Consulting fees	X None
5	Doumont or honoraria for	M Nows
	Payment or honoraria for	XNone
	lectures, presentations,	
	speakers bureaus, manuscript writing or	
	educational events	
		N N
	Payment for expert	XNone
1	testimony	
	Support for attending	XNone
1	meetings and/or travel	
8	Patents planned, issued or	V None
	pending	XNone
1	pending	
-		
	Participation on a Data	XNone
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	XNone
i	in other board, society,	
	committee or advocacy	
1	group, paid or unpaid	
	Stock or stock options	X None
12	Receipt of equipment,	XNone
	materials, drugs, medical	
	writing, gifts or other	
	services	
		M Nows
13	Other financial or non-	XNone
1	financial interests	